Billions of dollars are spent on dieting in this country alone. How do you know what to recommend to your patients? Dr Eisenson and Dr. Binks discuss the pros and cons of popular diet programs.
Recommending Diet Programs to Your Patients
Share this program on:
Choose a format
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Details
Presenters
Recommended
Details
Presenters
Overview
Billions of dollars are spent on dieting in this country alone. How do you know what to recommend to your patients? Dr Eisenson and Dr. Binks discuss the pros and cons of popular diet programs.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
COVID-19: On The Frontlines
How COVID-19 Is Affecting Life Outside of the Office: A Dermatologist’s Experience
<p>How COVID-19 Is Affecting Life Outside of the Office: A Dermatologist’s Experience</p>
CME/CE
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
0.25 credits
<p>Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective</p>
Medical Industry Feature
Gene Therapy: Changing the Landscape of Hemophilia B Care
<p>Gene Therapy: Changing the Landscape of Hemophilia B Care</p>
CME/CE
Partnering for Progress: A Case Study in Patient-Centered Hyperkalemia Management
0.25 credits
<p>Partnering for Progress: A Case Study in Patient-Centered Hyperkalemia Management</p>
GI Insights
Key Considerations for Second-Line PBC Treatment
<p>Key Considerations for Second-Line PBC Treatment</p>
CME/CE
Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities
0.25 credits
<p>Patient Partners in NSCLC: Collaborating to Enhance Quality of Life and Outcomes With EGFRi-Associated Dermatologic Toxicities</p>
ACC Action Center
Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D
<p>Phase 3 study with oral semaglutide meets primary endpoint in high-risk T2D</p>
ACC Action Center
Lorundrostat lowers BP in uncontrolled and treatment-resistant hypertension
<p>Lorundrostat lowers BP in uncontrolled and treatment-resistant hypertension</p>
Register
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?